Filing Overview
Xeris Biopharma Holdings, Inc. filed a Form 8-K on October 8, 2021, reporting events effective October 5, 2021. The filing concerns the completion of the previously announced transactions with Strongbridge Biopharma plc and Xeris Pharmaceuticals, Inc.
Business Context and Transaction
Xeris Holdco completed the acquisition of Strongbridge pursuant to a scheme of arrangement under Irish law and completed the merger of Wells MergerSub, Inc. with and into Xeris Pharmaceuticals, Inc. Xeris survived the merger. Following completion, both Xeris and Strongbridge became wholly owned subsidiaries of Xeris Holdco.
Capitalization and Financial Metrics
- Approximately 124.6 million Xeris Holdco shares were issued and outstanding as of the close of business on October 5, 2021.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial performance metrics.
- The filing does not provide financial guidance or pro forma financial information related to the transactions.
Material Changes and Other Items
Equity held by former Xeris officers and directors was exchanged for Xeris Holdco equity on a one-for-one basis. These exchanges were reported on Form 4 filings filed on October 5, 2021. The filing states that no sales into the open market were made by the former Xeris officers or directors at closing.
Outlook, Risks, and Contingencies
The filing does not provide management commentary, forward guidance, transaction synergies, integration expectations, new risks, contingencies, or unusual accounting items.
Investor Verification Items
- Verify the final share count and ownership structure of Xeris Holdco following the acquisition and merger.
- Review subsequent filings for transaction accounting, purchase-price allocation, pro forma results, debt, liquidity, and integration costs.
- Review the related Form 4 filings to confirm the equity exchanges involving former Xeris officers and directors.
- Assess future filings for operational performance, guidance, and risks associated with combining Xeris and Strongbridge.